Tofacitinib for the treatment of antineutrophil cytoplasm antibody-associated vasculitis: a pilot study

Ann Rheum Dis. 2021 Dec;80(12):1631-1633. doi: 10.1136/annrheumdis-2021-220484. Epub 2021 Aug 6.

Authors

Yun Liu¹, Zongfei Ji¹, Wensu Yu¹, Sifan Wu¹, Huiyong Chen¹, Lili Ma¹, Zhenqi Ding¹, Lindi Jiang²

Affiliations

¹ Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China.
² Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai, China zsh-rheum@hotmail.com.

PMID: 34362745
DOI: 10.1136/annrheumdis-2021-220484

No abstract available

Keywords: autoimmune diseases; granulomatosis with polyangiitis; systemic vasculitis; treatment.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / drug therapy*
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / metabolism
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / physiopathology
Blood Sedimentation
C-Reactive Protein / metabolism
Churg-Strauss Syndrome / drug therapy
Churg-Strauss Syndrome / metabolism
Churg-Strauss Syndrome / physiopathology
Female
Granulomatosis with Polyangiitis / drug therapy
Granulomatosis with Polyangiitis / metabolism
Granulomatosis with Polyangiitis / physiopathology
Humans
Janus Kinase Inhibitors / therapeutic use*
Male
Microscopic Polyangiitis / drug therapy
Microscopic Polyangiitis / metabolism
Microscopic Polyangiitis / physiopathology
Middle Aged
Pilot Projects
Piperidines / therapeutic use*
Pyrimidines / therapeutic use*
Treatment Outcome
Young Adult

Substances

Janus Kinase Inhibitors
Piperidines
Pyrimidines
tofacitinib
C-Reactive Protein